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Summary Transforming growth factor-PI (TGF-P1) is inhibitory for breast epithelial cells in vitro and
treatment of breast cancer cell lines with tamoxifen results in a rise in TGF-P1 mRNA expression with
associated inhibition of cell growth. To study whether these findings apply in vivo we examined TGF-p1
mRNA expression in an oestrogen-dependent mouse xenograft system following systemic treatment of the
mice with tamoxifen. In agreement with in vitro studies, TGF-P1 mRNA expression was sustained at high
levels and associated with a reduction in tumour size. A subsequent study of breast tumour tissue from 56
patients demonstrated high levels of TGF-P1 mRNA in 45 of the tumours. High expression was found to
correlate with premenopausal status, but not with tumour oestrogen receptor content or other parameters. In
a subgroup of 11 patients who had received tamoxifen therapy for 3 to 6 months prior to surgery,
unexpectedly high levels ofTGF-P1 mRNA were demonstrated in tumours increasing in size and unresponsive
to tamoxifen. Data from this study indicate that in patients with breast cancer, TGF-PI in the tumour may
not behave as in vitro and xenograft studies have suggested. We speculate that failure of tamoxifen therapy
may be due to failure of the autocrine inhibitory functions of TGF-P1 either alone or in combination with
paracrine stimulation of stromal cells or angiogenesis and localised immunosuppression. Further studies of
active TGF-p1, TGF-P receptors and the interactions with other growth factors will be required to elucidate
the precise role of TGF-P1 in human breast cancer and in the failure of tamoxifen therapy.
The transforming growth factor , (TGF-P) family are highly
potent polypeptides first characterised from transformed
fibroblasts (Derynck et al., 1985). At least three forms are
now recognised, TGF-p1, TGF-P2 amd TGF-1I.2 which
result from various combinations of the 25 kd PI and P2
subunits linked to form dimers by disulphide bonds (Cheifetz
et al., 1987). With the three TGF-P cell surface receptors of
65 kd, 85 kd and 20 kd (Massague 1987), which bind the
three forms of TGF-P differentially, a varied and complex
series of distinct signals can be generated (Hsuan, 1989). This
allows for different responses in different cell types and for
flexibility of the regulation of tissue growth and
differentiation by the TGF-P system (Cheifetz et al., 1987).
A role for the TGF-P family has been described not only
in viral transformation of cells (Anzano et al., 1987) and
carcinogenesis (Sporn et al., 1987) but also in embryonic
development (Massague, 1987; Roberts et al., 1988). The
wide range of possible biological activities for the TGF-P
family is dependent on the cell type, the degree of cell
differentiation and the other growth factors present (Roberts
et al., 1985; Roberts et al., 1988). TGF-P can stimulate or
inhibit cell proliferation depending on the experimental con-
ditions or type of cells (Tucker et al., 1984; Roberts et al.,
1985; Sporn et al., 1987), with TGF-P1 and TGF-P2 strongly
inhibitory on some epithelial derived cell lines (Tucker et al.,
1984). For mammary epithelial cells in vitro, TGF-P1 is
inhibitory for cell growth (Sporn et al., 1987; Knabbe et al.,
1987; Lippman et al., 1987) with TGF-PI ten times more
active than TGF-,B2 at inhibiting growth of the oestrogen
dependent breast cancer cell line MCF-7 (Arrick et al., 1990).
TGF-P11 mRNA has been detected in a wide range of cell
lines and tumour tissues (Derynck et al., 1985; Knabbe et al.,
1987) with low or undetectable levels in normal tissue
(Derynck et al., 1985) and higher levels in tumour when
compared to adjacent normal tissues (Derynck et al., 1985;
Coombes, 1989). In addition, the anti-oestrogen tamoxifen
induces TGF-13 mRNA production in vitro, but has no effect
on the species of TGF-P mRNA expressed (Arrick et al.,
1990) supporting the thesis that TGF-P1 stimulation is a
mechanism of tamoxifen action against breast cancer cells
(Knabbe et al., 1987). However, in apparent contradiction to
this, MCF-7 cells transfected with the v-Ha-ras oncogene
grew rapidly despite enhanced constitutive production of
TGF-P1 (Dickson et al., 1987).
Given the interest which such in vitro studies have aroused
and the possible involvement ofTGF-P1 in the mechanism of
action of tamoxifen, we sought to examine TGF-P1 expres-
sion in vivo, at the mRNA level, since detection of an mRNA
implies dynamic production of the gene product. This paper
presents studies of TGF-P1 mRNA expression in an
oestrogen-dependent xenograft system, in human breast
tumours and in breast tumours from patients who have
received tamoxifen prior to surgery.
Materials and methods
Tamoxifen treatment ofmouse xenograft tumours
An oestrogen-dependent xenograft system has been de-
veloped by injecting a single dose of 107 viable MCF-7 cells
into immune-compromised CBA mice (Thompson et al.,
1990). The effect of tamoxifen treatment on tumour growth
in this xenograft model was studied. A batch of ten mice
each bearing on established single transplanted xenograft
tumour of mean volume 250mm3 received 50 lg 17p oest-
radial benzoate in arachis oil injected subcutaneously into the
groin as previously described (Thompson et al., 1990). This
single injection is sufficient to sustain further xenograft
growth for 3 weeks (Thompson et al., 1990). Tamoxifen
(Nolvadex, ICI 46, 474) was dissolved in arachis oil and
1.25 mg injected daily, subcutaneously, into the hindquarter
area, 2cm from the xenograft. The dose of tamoxifen was
calculated in milligrams of tamoxifen per kilogram body
weight based on the human dose and tested for toxicity at
1.25 mg day-' on mice which had not received exogenous
oestrogen. The series of tamoxifen injections commenced on
the same day as the administration of the single dose oest-
rogen supplement. The tumours were measured daily using
calipers, two mice killed and tumour material excised for
study at 2, 4, 7, 14 and 21 days after commencing tamoxifen
therapy. All tumours were snap frozen in liquid nitrogen for
subsequent total RNA extraction after tissue had been
removed for pathological examination and oestrogen recep-
tor protein estimation.
Human tumour material
Fresh primary breast cancer tissue was obtained at operation
from 56 patients with fully documented history, examination,
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staging investigations and subsequent follow-up, who pre-
sented with operable breast cancer to the Department of
Surgery Breast Unit at Longmore Hospital, Edinburgh. Of
the 56 women (age range 34 to 84 years), 11 (all age over 70
years) required surgery due to failure of tamoxifen therapy
(20 mg per day orally). These 11 tamoxifen-treated patients
underwent mastectomy for tumour progression (increase in
tumour size over a 3-6 month period; six patients) or lack of
response to tamoxifen (tumour static in size over a 6 month
period; five patients) assessed on clinical (caliper) and
radiological grounds.
Tumour tissue from patients who underwent wedge biopsy,
local excision or mastectomy as primary therapy for
confirmed carcinoma of the breast, or following failure of
tamoxifen therapy, was frozen in liquid nitrogen and stored
at - 70°C. Tissue immediately adjacent to that frozen was
fixed for histopathology and a further piece of tumour sub-
mitted for oestrogen receptor assay. For comparison with
constitutional DNA, 20 ml of venous blood was withdrawn
for DNA extraction. Breast tissue from ten patients who
underwent cosmetic reduction mammoplasty and who did
not have a personal or family history of breast cancer was
also obtained fresh and snap frozen.
The breast cancer cell lines MCF-7 (Soule et al., 1973),
MDA-MB-231 (Cailleau et al., 1974) and T-47D (Keydar et
al., 1979) were cultured and maintained under standard
mycoplasma-free conditions (Barile, 1973). They were
harvested in the logarithmic phase of growth and the total
RNA was extracted for comparison with that from the
tumours.
Ribonucleic acid extraction
From frozen tumour, total ribonucleic acid (RNA) was ex-
tracted using a modification of the method of Auffrey and
Rougeon (1980). Briefly, a known weight of frozen tumour
or a known number of cells washed in phosphate buffered
saline was pulverised and then disrupted in 2 ml 3 M lithium
chloride/6 M urea per 100 mg tissue and precipitated at 4°C
overight. The DNA was sheared using a Soniprep 150 ultra-
sonic disintegrator (MSE Scientific Instruments, Crawley,
UK) with an ice jacket, the RNA was recovered by centri-
fugation at 12,000 r.p.m. and the pellet was taken up in 6 ml
of 10 mMol Tris buffer pH 7.0/0.1% sodium dodecyl sul-
phate (SDS). Three hundred micrograms ofproteinase K was
added and the sample was incubated at 37°C for 20min.
Protein was extracted using phenol equilibrated with tris
(0.1 M, pH 7) and chloroformn:isoamylalcohol (24:1).
Following ethanol precipitation of the aqueous phase at
- 20°C, the RNA was recovered by centrifugation and dis-
solved in autoclaved distilled water treated with diethyl
pyrocarbonate (DEPC, Sigma, USA) and stored in aliquots
at - 70°C. The quantity and purity of the RNA was assessed
by spectrophotometry at 260 nm and 240 nm.
Throughout the RNA extraction procedures, sterile dis-
posable plastic ware was used where possible; all solutions
were made up with autoclaved, DEPC-treated water using
baked glassware and gloves were worn to minimise
exogenous ribonuclease contamination (Maniatis et al.,
1982).
Electrophoresis and transfer ofRNA
Twenty micrograms of total RNA was denatured with for-
mamide and formaldehyde at 55°C for 20 min; 2ftl loading
buffer (50% glycerol, ImM EDTA 0.4% bromophenol blue,
0.4% xylene cyanol) and 1 1l of 10 tLg ll-' ethidium bromide
were added to each sample. The denatured specimens were
loaded onto a 1.1% agarose gel containing 0.66M formal-
dehyde, submerged beneath MOPS buffer (morpholinopro-
panesulphonic acid 0.2M, pH 7.0, 50mM sodium acetate
pH 7.0, 5 mM EDTA) and the RNA species were separated
electrophoretically (method modified from Fourney et al.,
1988).
The gel was washed in two changes of 10 x standard saline
citrate (1 x SSC contains 150 mM sodium chloride, 15 mM
sodium citrate, 1 mM EDTA, pH 7.4), photographed under a
UV transilluminator and the RNA was transferred to a
nylon filter (Hybond-N, Amersham, UK) by capillary action
using 10 x SSC over 8 h (method modified from Southern,
1975). The filter was rinsed in 2 x SSC, air-dried and the
RNA was covalently fixed to the membrane using a UV
transilluminator. The filter and remaining gel were photo-
graphed to check for adequate transfer of the RNA.
Probe hybridisation
To detect the TGF-P1 mRNA, the 1.05 kb cDNA insert cut
from plasmid sp65-Cl7N (Derynck et al., 1985) was used.
Filters were prehybridised in 7% SDS, 0.5 M disodium hy-
drogen phosphate (pH 7.2) and 1 mMol EDTA pH 7.0
(method modified from Church & Gilbert, 1984) for 30min
at 65°C. To this was added 32p cytidine triphosphate (CTP) -
labelled cDNA probe, with specific activity to 1 x 107 c.p.m.
ml-' achieved using a randomprime DNA-labelling system
(Boehringer Mannheim, West Germany). 32P-CTP incor-
porated probe was separated from unincorporated radio-
nucleotide using a Sephadex column (Nick column,
Pharmacia, UK) and denatured before addition to the hy-
bridisation solution.
Following 24 h hybridisation, filters were washed to
remove non-specifically attached probe in two changes of
0.1% SDS 10mMol disodium hydrogen phosphate wash
buffer at 65°C with agitation. The filters were blotted dry,
wrapped in cling film and exposed to preflashed Kodak XAR
film at - 70°C overnight and then for up to 14 days.
The filter was washed clean of the TGF-P1I probe by
incubation at 80C in 0.1% SDS for 30min and reprobed
with a standard probe (the 1.4 kb Pstl insert cDNA for actin
mRNA; Minty et al., 1981), the expression of which is not
affected by oestrogen (Saceda et al., 1988), to quantify the
amount of intact mRNA present.
The extent of hybridisation of radiolabelled probe to the
mRNA species was determined from laser densitometry and
expressed with respect to hybridisation of the actin probe.
The size of the TGF-PI mRNA species was calculated from
the position of ribosomal RNA markers.
Oestrogen receptors
The oestrogen receptor content was measured using the
Enzyme Immunosorbent Assay (EIA; kit from Abbot
Laboratories, North Chicago, Illinois; Hawkins et al., 1987)
and expressed in fmol mg total protein-'. Oestrogen receptor
protein concentrations of 20 fmolmg protein-' or greater
were considered to be clinically significant (Anderson et al.,
1989).
Results
Tamoxifen treatment ofMCF-7 xenograft tumours
Sequential xenograft tumour measurement demonstrated
tumour regression over the 21 day period of tamoxifen treat-
ment (Figure 1), rather than the expected increase in tumour
size to approximately 800 mm3. Northern blot studies of
TGF-P1 mRNA expression, as a percentage of actin control,
demonstrated increased expression from very low levels at
day 0 to a sustained, high level of expression from days 7 to
21 (Figure 1).
Human tissues
Intact mRNA for TGF-PI of 2.5 kilobases (kb) in size was
detected in all the tumour specimens and was also detected in
normal breast tissues (Figure 2). High expression of TGF-Pl
(>2 x that of normal breast tissue) was found in 45 of the
56 tumours (Table Ia).
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Figure 1 Effect of tamoxifen treatment on MCF-7 xenograft
tumour TGF-PI mRNA. Tumour regression (solid line) following
tamoxifen administration, associated with a sustained rise in
TGF-P1 mRNA (hatched line). 17p oestrodiol benzoate in arachis
oil was administered at time =O (arrow); daily injection of
1.25 mg tamoxifen is indicated (T). TGF-PI mRNA expression is
expressed as a percentage of the actin mRNA signal from laser
densitometry of the same Northern blot. Tumour volume was
calculated from the equation: volume = pi/12 x mean diameter3.
high expression of mRNA for TGF-pl. There was a
significant correlation between high expression of TGF-13I
and premenopausal status (P = 0.05, Fisher's exact test).
There was no significant correlation between expression of
mRNA for TGF-Pi1 and tumour size, tumour oestrogen
receptor protein expression or the presence of axillary nodal
metastasis (Table la). Tumour tissue predominated over nor-
mal tissues in all the tumour specimens.
In the subgroup of 11 tamoxifen treated postmenopausal
women (Table lb), the six tumours increasing in size had
high levels of TGF-P1 expression; 4 of the 5 static tumours
had low levels of mRNA for TGF-P1.
In the six patients who exhibited breast tumours increasing
in size despite tamoxifen therapy all the tumours expressed
high levels of TGF-P1 mRNA in the tumour material and
had oestrogen poor tumours (oestrogen receptor protein less
than 20fmolmg protein-'). From the five patients with
tumours static in size following tamoxifen treatment, only
one patient was oestrogen receptor poor and the same
patient expressed high levels of TGF-PI mRNA; the remain-
ing four patients (who had oestrogen receptor moderate or
Actin
Figure 2 TGF-P1 mRNA expression in human breast cancer.
Autoradiographs of representative Northern blots from six
human breast tumours. a, 2 breast tumours growing (i.e. unin-
hibited) on tamoxifen treatment. b, 2 tumours static on tamoxifen
treatment. c, 2 untreated breast tumours. One sample of normal
breast tissue. d, and 3 breast cancer cell lines. e, MCF-7, T47-D,
MDA-MB-231, left to right). The figure demonstrates the 2.5 kb
TGF-PI mRNA and the 1.8 kb actin signals for the same re-
probed filter.
rich tumours with greater than 20fmol mg protein-') had
low levels of mRNA for TGF-pl.
Discussion
We have examined TGF-13I gene expression at the mRNA
level in xenografts treated with tamoxifen and in 56 human
breast tumours, 11 ofwhich had been treated with tamoxifen
prior to surgery. The MCF-7 oestrogen-dependent xenografts
confirm the effect oftamoxifen on MCF-7 cells demonstrated
in vitro (Knabbe et al., 1987). Tamoxifen treatment of the
xenograft tumours was associated with a sustained rise in
TGF-13I mRNA to levels only briefly attained in the un-
treated tumours (Thompson et al., 1990) and a reduction in
tumour volume.
We have confirmed that TGF-P1 mRNA can be isolated
and quantified from human breast tissue and breast cancer
cell lines and that the 2.5 kb TGF-P1I mRNA is the same size
as that detected by other workers (Knabbe et al., 1987;
Travers et al., 1988).
This study demonstrates that a high level of mRNA for
TGF-1I detected in breast cancer tissue correlates with
premenopausal status but confirms that there is no associa-
Table I TGF-P1 mRNA levels in breast cancer tissue in relation to clinical and
pathological characteristics
TGF-P1 mRNAa Probability
Characteristic Low High (Fishers Exact Test)
(a) Allpatients (n = 56)
Pre-menopausalb(n = 19) 1 18
Pre-menopausalb (n = 37) 10 27 0.05
Tumouroestrogenreceptor 7 23
>20 fmol mgprotein-' (n = 30) NS
Tumouroestrogen receptor 4 22
<20 fmol mgprotein-' (n = 26)
Tumoursize > 5 cmmeandiameter 2 20
(n = 22) NS
Tumour size >5 cm meandiameter 9 25
(n = 34)
Histologyinvolved nodes (n = 28) 7 21 NS Nonodemetastasis (n = 28) 4 24
(b) Tamoxifen-pretreatedpatients(n = 11)
Disease static (n = 5) 4 1
Disease progressing (n = 6) 0 6
'Assessment based on intensity ofTGF-PI signal relative to that for actin. Specimens
clearly fell into two groups, 50% ofactin signal or less ('low') as in normal breast tissue
and greater than 100% of actin signal ('high') on 24h radiographs. bBased on men-
strual history and, in perimenopausal women, on measurement of serum FSH and LH.
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tion with oestrogen receptor protein content (Travers et al.,
1988). There is also an association between a high level of
mRNA for TGF-P1 and progression of breast cancer despite
tamoxifen treatment. On the basis of in vitro studies (Knabbe
et al., 1987) we had expected low levels of TGF-P1 gene
transcription in tumours growing despite tamoxifen therapy,
releasing the cells from proliferative constraints (Sporn &
Roberts, 1985). However, high levels of TGF-PI mRNA and
clinically insignificant levels of oestrogen receptor protein
(Anderson et al., 1989) were found in this group of human
breast tumours. By contrast, patients in whom tamoxifen
therapy had induced tumour stasis (but not regression) had
low levels of TGF-P1 mRNA, but in most cases the tumour
contained oestrogen receptor protein of greater than
20 fmol mg-' total protein. The association between high
TGF-13 mRNA expression and the failure of tamoxifen
therapy may therefore be co-incidental given that these were
oestrogen poor tumours. Against this proposition is the lack
of correlation between TGF-P1 mRNA expression and oest-
rogen receptor protein, both in this work (Table Ta) and in
one previous study (Travers et al., 1988), and the inhibitory
effect of TGF-P1 on oestrogen receptor poor MDA MB 231
cells in vitro (Knabbe et al., 1987). The data are also unlikely
to be due to a direct effect of tamoxifen on TGF-P1 or due to
TGF-P1 degradation (Knabbe et al., 1987), although long
term oestrogen deprivation of T-47D cells in vitro is
associated with upregulation of TGF-11 mRNA expression
(King et al., 1989). Since tumour cells predominated over
stromal cells and cells of haemopoietic origin, the difference
between in vitro and human tissue studies are unlikely to be
due to the presence of normal cells. However, in situ studies
would demonstrate the distribution of the cells producing
TGF-31.
The unexpected finding of high TGF-P1 gene transcription
in tamoxifen insensitive, growing breast cancers merits fur-
ther consideration. We propose that two possible
mechanisms may be involved: failure of the autocrine
inhibitory feedback pathway on the cancer cells themselves
and/or paracrine stimulation by the TGF-p1.
One mechanism for the escape from the autocrine
inhibitory effects of TGF-P11 on the breast cancer cells
(Figure 3) may be due to the failure to activate secreted
TGF-13I (Hsaun, 1989), over 98% of which is secreted in
inactive from (Wakefield et al., 1987) an established control
point for MCF-7 in vitro (Knabbe et al., 1987).
Alternatively cells may fail to respond to the negative
stimulus (Roberts et al., 1985) or respond weakly (Parkinson,
1985) due to reduction or loss of receptor function. The
tumour cells may be resistant to the growth-inhibitory effects
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Figure 3 A diagramatic representation of the autocrine and
paracrine pathways for TGF-p1. The potential actions of TGF-P1
in breast cancer tissue: a, the autocrine inhibitory pathway
whereby TGF-P1 produced by a breast cancer cell (as mRNA
translated to protein precursor) is activated and acts via TGF-P1
receptors to inhibit the cell and, b, the paracrine stimulation of
other cells and tissues or inhibition of immune response within
the tumour.
of TGF-P1 as has been demonstrated in vitro (Valverius et
al., 1989) perhaps due to lack of functional TGF-P1 receptors
as occurs in retinoblastoma (Kimchi et al., 1988).
There may be a mechanism similar to that observed fol-
lowing viral transformation of cells, where increased TGF-P1
secretion is associated with downregulation of the TGF-PI
receptors in the same cells (Anzano et al., 1985). However,
transformation to full malignant potential and associated
escape from TGF-P1 growth inhibition can occur without
affecting TGF-P1 production or receptor characteristics
(Valverius et al., 1989). Modulation of ligand-receptor bind-
ing may not be an important control mechanism in some
systems (Wakefield et al., 1987), where modulation of TGF-
1P responsiveness may occur at the level of signal transduc-
tion (Valverius et al., 1989).
TGF-P1 may even directly stimulate the breast cancer cells,
compatible with the in vitro observation that upregulation of
TGF-P1 mRNA is accompanied by apparent stimulation (by
the transcribed TGF-P1) of T-47D cells rendered steroid
insensitive (King et al., 1989). It has also been proposed that
tumour progression in one mouse mammary tumour model
may, at least in part, be due to increased TGF-P1 expression
(Cato et al., 1990). Thus one or more defects in the autocrine
inhibitory TGF-P1I pathway may result in the failure of
TGF-P1 inhibition on breast cancer cells in vivo.
A second, paracrine mechanism may also be involved
(Figure 3). Stromal growth may be enhanced by increasing
the levels of fibroblast mutagens such as interleukin 1 (Sporn
et al., 1987). TGF-P species can greatly enhance accumula-
tion of extracellular matrix (Massague, 1987), reduce proteo-
lytic degradation by fibroblasts (Roberts et al., 1988) and
increase the levels of mRNA for collagen and fibronectin (in
normal rat kidney cells; Sporn et al., 1987). TGF-ps may act
as chemotactic agents for macrophages (presumably stimu-
lating them to secrete angiogenic peptides) and as potent
stimulators of angiogenesis in vivo (Roberts et al., 1986;
Sporn et al., 1987). In addition the local immunosuppressive
effect of TGF-P1 (Kerhl et al., 1986; Sporn et al., 1987;
Wrann et al., 1987; Carel et al., 1990; Torre-Amoine et al.,
1990) may also play a crucial role.
Given the mRNA and protein distribution of epithelial
TGF-,B1 (Akhurst et al., 1988), some combination of auto-
crine defect or paracrine effects on the supporting stroma
may occur. The present study does not address the questions
of TGF-P1 activation or receptor function which may be
important in this as in other settings (Knabbe et al., 1987;
Hsuan, 1989). A further indication that the in vivo situation
may be more complex than in vitro studies have suggested is
the significant correlation between high TGF-P1 mRNA ex-
pression and premenopausal status identified in this study.
This may be explained by the local effects of TGF-p1,
activitystranscribed at a high rate in the breast tumour cells,
dominating the effects of systemically circulating oestrogens
which one might expect from in vitro studies to inhibit TGF-
P1 transcription (Dickson et al., 1987).
There may also be critical interactions between TGF-P1
and other growth factors (Roberts et al., 1986; Fernandez-pol
et al., 1987) particularly epidermal growth factor and TGF-
alpha also detected in breast tumour tissue (Travers et al.,
1988). As additional considerations, TGF-P1 may be
negatively regulated by binding to factors such as the proteo-
glycan decorin (Yamaguchi et al., 1990), itself induced by
TGF-p1, or may act in a common growth inhibitory pathway
with the retinoblastoma protein maintaining the protein in an
underphosphorylated, growth-suppressive state (Laiho et al.,
1990). Certainly, the effects of tamoxifen on breast cells even
in vitro are complex and other factors may well be involved
(May & Westley, 1987; Johnson et al., 1989; Berry et al.,
1989).
While the demonstrated inhibitory action of TGF-P1 on
breast cancer cells and the effect of tamoxifen on TGF-P1
mRNA and cell growth in vitro are compatible with our
findings in the oestrogen-dependent mouse xenograft system,
the findings using human tissues merit further investigation.
We propose that in tumours where tamoxifen fails to work inTGF-P1 AND TAMOXIFEN FAILURE IN BREAST CANCER 613
vivo, there may not only be breakdown at one or more points
of the TGF-131 autocrine inhibitory loop, but additional
paracrine effects mediated by TGF-p1, including stimulation
of stromal growth and angiogenesis and escape from
immunological surveillance. The net effect of tamoxifen in a
subgroup of tumours may therefore be to stimulate tumour
cell growth via the TGF-01 system. With the recent demon-
stration that antiserum to TGF-P1 can suppress an experi-
menally induced disease state (Border et al., 1990), further
analysis of TGF-P1 in breast cancer may identify potential
therapeutic avenues. Certainly, the findings from this study
suggest that the role of TGF-P1 in regulating the growth of
human breast cancer, including tumour response to therapy,
should be re-evaluated.
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